Business Context and Reporting Period
Company: Leap Therapeutics, Inc. (formerly Dekkun Corporation and HealthCare Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2016
Business Overview: Leap is a clinical-stage biopharmaceutical company developing novel therapeutics for cancer. Its pipeline consists of two primary monoclonal antibody programs: DKN-01 (targeting DKK1 for esophagogastric, biliary tract, and lung cancers) and TRX518 (targeting GITR for advanced solid tumors). The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(25.6) million | $(12.1) million |
| Accumulated Deficit | $(100.7) million | $(70.4) million |
| Research & Development Expenses | $23.3 million | $10.4 million |
| General & Administrative Expenses | $4.2 million | $1.5 million |
| Cash and Cash Equivalents (Year End) | $0.8 million | $0.4 million |
| Notes Payable (Related Party) | $30.3 million | $3.1 million |
| Australian R&D Incentive Income | $3.1 million | $0 |
Note: The company reported no revenue. The "Australian R&D Incentive Income" is recorded as other income, not product revenue.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss more than doubled from $12.1 million in 2015 to $25.6 million in 2016, driven primarily by a $12.9 million increase in R&D expenses and a $2.7 million increase in G&A expenses.
- R&D Spend Surge: R&D expenses rose significantly due to increased manufacturing of clinical trial materials for DKN-01 and TRX518, expanded clinical research activities, and higher compensation costs.
- Debt Financing: The company raised $25.9 million in proceeds from convertible promissory notes issued to related parties (HealthCare Ventures funds) during 2016, compared to $5.0 million in 2015. This debt carried an 8% interest rate.
- Government Incentives: The company recognized $3.1 million in Australian R&D tax incentive income in 2016, a new revenue stream not present in 2015.
Guidance, Outlook, and Risks
Outlook and Liquidity: As of December 31, 2016, the company held only $0.8 million in cash. Management stated that this balance, combined with the $21.2 million in cash acquired from the Macrocure merger (closed January 23, 2017), a $10.0 million equity investment by existing shareholders, and the anticipated $3.1 million R&D tax incentive, would fund operations through at least March 2018. The company expects to continue incurring significant losses as it advances clinical trials.
Recent Developments (Post-Period): On January 23, 2017, the company consummated a merger with Macrocure Ltd., acquiring its TRX518 program. Concurrently, all outstanding related-party notes and accrued interest were converted into common stock.
Key Risks:
- Capital Needs: The company has no product revenue and requires substantial additional capital to fund clinical trials and commercialization. Failure to secure funding could force delays or termination of programs.
- Clinical Uncertainty: Both DKN-01 and TRX518 are investigational drugs. Preliminary data is promising, but there is no guarantee of regulatory approval or commercial success.
- Intellectual Property: The company faces opposition proceedings regarding its TRX518 patents in Europe, which could limit its ability to prevent competition.
- Going Concern: The filing includes a "Going Concern" disclosure, noting that the company has incurred losses since inception and its future operations depend on raising additional capital.
Investor Verification Checklist
- Cash Runway: Verify the actual cash position post-merger (January 2017) and confirm the receipt of the $3.1 million Australian R&D tax incentive.
- Debt Conversion: Confirm the terms and share count resulting from the conversion of the $30.3 million related-party debt into equity.
- Clinical Trial Data: Review the full data sets from the DKN-01 (esophagogastric and biliary tract) and TRX518 (solid tumors) Phase 1/2 trials to assess the robustness of the preliminary results cited.
- Patent Status: Monitor the outcome of the European Patent Office opposition proceedings regarding the TRX518 patents.
- Merger Integration: Assess the integration of Macrocure's operations and the combined pipeline strategy.